[ORGANIZATION]
Skyrizi
Featured in 6 tracked stories · first seen
Situations
AbbVie financial performance and strategic transition
2 clusters · 8 sources · last updated
Latest: AbbVie raises profit guidance following strong Q3 results
AbbVie is undergoing a strategic shift in its pharmaceutical focus, moving from its legacy product Humira toward new immunology and oncology treatments. In fiscal year 2025, the company reported revenue of $61.2 billion,
Also covered in
-
FDA approves subcutaneous Skyrizi induction for Crohn’s disease
[HEALTH] · 7 sources ·